Wang Tiansheng, Pate Virginia, Wyss Richard, Buse John B, Kosorok Michael R, Stürmer Til
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Am J Epidemiol. 2025 Jun 11. doi: 10.1093/aje/kwaf127.
We tested a novel high-dimensional approach (using 1 ordinal variable per code with up to four levels: zero, occurred once, sporadically, or frequent) against the standard high-dimensional propensity score (hdPS) method (up to 3 binary variables per code) for detecting heterogeneous treatment effects (HTE). Using the iterative causal forest (iCF) subgrouping algorithm, we analyzed a new-user cohort of 8,075 sodium-glucose cotransporter-2 inhibitors and 7,313 glucagon-like peptide-1 receptor agonists from a 20% random Medicare sample (2015-2019) with ≥1-year parts A/B/D enrollment and without severe renal disease. We extracted the top 200 prevalent codes across diagnoses, procedures, and prescriptions during the 1-year baseline. Subgroup-specific conditional average treatment effects (CATEs) were assessed for 2-year risk differences (aRD) in hospitalized heart failure using inverse-probability treatment weighting. The overall population exhibited an aRD of -0.4% (95% CI -1.1%, 0.2%). Our high-dimensional setting identified patients with ≥2 loop diuretic prescriptions (aRD: -2.6%, 95% CI: -5.0%, -0.2%) as the subgroup with the largest CATE. In contrast, the high-dimensional setting from hdPS identified patients with chronic kidney disease (aRD: -1.7%, 95% CI: -3.6%, 0.2%). Across various sensitivity analyses, our high-dimensional approach more accurately identified expected subgroups with HTE that aligns with prior clinical evidence.
我们针对标准的高维倾向评分(hdPS)方法(每个编码最多使用3个二元变量),测试了一种新型高维方法(每个编码使用1个有序变量,最多有四个级别:零、发生一次、偶发或频繁),以检测异质性治疗效果(HTE)。使用迭代因果森林(iCF)亚组划分算法,我们分析了来自20%随机医疗保险样本(2015 - 2019年)的8075名钠-葡萄糖协同转运蛋白2抑制剂使用者和7313名胰高血糖素样肽-1受体激动剂使用者的新用户队列,这些使用者A/B/D部分参保≥1年且无严重肾病。我们在1年基线期提取了诊断、手术和处方中最常见的200个编码。使用逆概率治疗加权法评估住院心力衰竭2年风险差异(aRD)的亚组特异性条件平均治疗效果(CATEs)。总体人群的aRD为-0.4%(95%CI -1.1%,0.2%)。我们的高维设定将≥2次袢利尿剂处方的患者(aRD:-2.6%,95%CI:-5.0%,-0.2%)确定为CATE最大的亚组。相比之下,hdPS的高维设定确定患有慢性肾病的患者(aRD:-1.7%,95%CI:-3.6%,0.2%)。在各种敏感性分析中,我们的高维方法更准确地识别出了与先前临床证据相符的具有HTE的预期亚组。